Table 2.
Participant follow-up
| BLSA | ADNI | |||
|---|---|---|---|---|
| A–, n = 71 | A+, n = 32 | A–, n = 61 | A+, n = 61 | |
| No. FTP PET per participant | ||||
| 1 | 41 (58%) | 18 (56%) | 34 (56%) | 26 (43%) |
| 2 | 21 (30%) | 9 (28%) | 18 (30%) | 22 (36%) |
| 3+ | 9 (13%) | 5 (16%) | 9 (15%) | 13 (21%) |
| No. PiB PET per participant | ||||
| 1 | 16 (23%) | 8 (25%) | — | — |
| 2 | 21 (30%) | 7 (22%) | — | — |
| 3 | 18 (25%) | 8 (25%) | — | — |
| 4+ | 16 (23%) | 9 (28%) | — | — |
| No. FDG PET per participant | ||||
| 1 | — | — | 23 (38%) | 37 (61%) |
| 2 | — | — | 32 (52%) | 20 (33%) |
| 3 | — | — | 6 (10%) | 4 (7%) |
| No. MRI per participant | ||||
| 1 | 3 (4%) | 1 (3%) | 15 (25%) | 27 (44%) |
| 2 | 12 (17%) | 8 (25%) | 29 (48%) | 25 (41%) |
| 3 | 26 (37%) | 11 (34%) | 16 (26%) | 9 (15%) |
| 4+ | 30 (42%) | 12 (38%) | 1 (2%) | — |
| FTP PET follow-up duration (years) | 2 (2, 2) | 2 (1, 3) | 2 (1, 2) | 2 (1, 2) |
| PiB PET follow-up duration (years) | 4 (2, 5) | 4 (3, 4) | — | — |
| FDG PET follow-up duration (years) | — | — | 4 (4, 5) | 4 (4, 5) |
| MRI follow-up duration (years) | 4 (4, 6) | 4 (4, 5) | 2 (1, 2) | 1 (1, 2) |
Continuous values are reported as median (interquartile range) and categorical values are reported as n (%). Follow-up duration is calculated as the interval between last and first scans included in the longitudinal analyses and its summary statistics are based on participants with at least two scans.
A– = amyloid negative; A+ = amyloid positive; — indicates that data are not available.